115 related articles for article (PubMed ID: 38355125)
1. Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition.
Zhang H; Lin J; Chen X; Dai J; Lin H
Endocr J; 2024 Apr; 71(4):417-427. PubMed ID: 38355125
[TBL] [Abstract][Full Text] [Related]
2. PTH1-34 promotes osteoblast formation through Beclin1-dependent autophagic activation.
Wu H; Xue Y; Zhang Y; Wang Y; Hou J
J Bone Miner Metab; 2021 Jul; 39(4):572-582. PubMed ID: 33818629
[TBL] [Abstract][Full Text] [Related]
3. Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway.
Liu S; Zhu L; Zhang J; Yu J; Cheng X; Peng B
Biochem Pharmacol; 2016 Apr; 106():82-93. PubMed ID: 26947453
[TBL] [Abstract][Full Text] [Related]
4. Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses.
Zhang G; Wang Y; Tang G; Ma Y
BMC Complement Altern Med; 2019 Oct; 19(1):269. PubMed ID: 31615565
[TBL] [Abstract][Full Text] [Related]
5. IL-17A inhibits the degradation of RANKL in osteoblasts by inhibiting BCL2-Beclin1-autophagy signaling.
Chen XX; Wu HJ; Ke DS; Zhu YR
In Vitro Cell Dev Biol Anim; 2023 Apr; 59(4):300-311. PubMed ID: 37002492
[TBL] [Abstract][Full Text] [Related]
6. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
[TBL] [Abstract][Full Text] [Related]
7. Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide.
Tang Y; Sun F; Li X; Zhou Y; Yin S; Zhou X
J Endod; 2011 Dec; 37(12):1653-8. PubMed ID: 22099899
[TBL] [Abstract][Full Text] [Related]
8. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
9. Porphyromonas gingivalis Stimulates Bone Resorption by Enhancing RANKL (Receptor Activator of NF-κB Ligand) through Activation of Toll-like Receptor 2 in Osteoblasts.
Kassem A; Henning P; Lundberg P; Souza PP; Lindholm C; Lerner UH
J Biol Chem; 2015 Aug; 290(33):20147-58. PubMed ID: 26085099
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide (LPS) induces the apoptosis and inhibits osteoblast differentiation through JNK pathway in MC3T3-E1 cells.
Guo C; Yuan L; Wang JG; Wang F; Yang XK; Zhang FH; Song JL; Ma XY; Cheng Q; Song GH
Inflammation; 2014 Apr; 37(2):621-31. PubMed ID: 24272171
[TBL] [Abstract][Full Text] [Related]
11. JNK1 regulates RANKL-induced osteoclastogenesis
Ke D; Ji L; Wang Y; Fu X; Chen J; Wang F; Zhao D; Xue Y; Lan X; Hou J
FASEB J; 2019 Oct; 33(10):11082-11095. PubMed ID: 31295022
[TBL] [Abstract][Full Text] [Related]
12. Hexokinase 2-mediated glycolysis promotes receptor activator of NF-κB ligand expression in Porphyromonas gingivalis lipopolysaccharide-treated osteoblasts.
Yu Y; Jiang L; Li J; Lei L; Li H
J Periodontol; 2022 Jul; 93(7):1036-1047. PubMed ID: 34585393
[TBL] [Abstract][Full Text] [Related]
13. The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation.
Liu FL; Chen CL; Lee CC; Wu CC; Hsu TH; Tsai CY; Huang HS; Chang DM
Int J Med Sci; 2017; 14(9):840-852. PubMed ID: 28824321
[TBL] [Abstract][Full Text] [Related]
14. Protective Effects of Pretreatment with Quercetin Against Lipopolysaccharide-Induced Apoptosis and the Inhibition of Osteoblast Differentiation via the MAPK and Wnt/β-Catenin Pathways in MC3T3-E1 Cells.
Guo C; Yang RJ; Jang K; Zhou XL; Liu YZ
Cell Physiol Biochem; 2017; 43(4):1547-1561. PubMed ID: 29035884
[TBL] [Abstract][Full Text] [Related]
15. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
[TBL] [Abstract][Full Text] [Related]
16. Rubiadin-1-methyl ether inhibits BECN1 transcription and Beclin1-dependent autophagy during osteoclastogenesis by inhibiting NF-κB p65 activation.
Cai S; Chen Y; Chen J; Wei W; Pan J; Wu H
Exp Biol Med (Maywood); 2023 Sep; 248(17):1518-1526. PubMed ID: 37750211
[TBL] [Abstract][Full Text] [Related]
17. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway.
Zheng L; Gao J; Jin K; Chen Z; Yu W; Zhu K; Huang W; Liu F; Mei L; Lou C; He D
FASEB J; 2019 Jun; 33(6):7667-7683. PubMed ID: 30893559
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17 promotes osteoclastogenesis and periodontal damage via autophagy in vitro and in vivo.
Zhong J; Wang Z; Yuan W; Shen Y; Chen L
Int Immunopharmacol; 2022 Jun; 107():108631. PubMed ID: 35219162
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite.
Sritharan S; Kannan TP; Norazmi MN; Nurul AA
J Craniomaxillofac Surg; 2018 Aug; 46(8):1361-1367. PubMed ID: 29805067
[TBL] [Abstract][Full Text] [Related]
20. Macrolactin A protects against LPS-induced bone loss by regulation of bone remodeling.
Sapkota M; Gao M; Li L; Yang M; Shrestha SK; Choi H; Soh Y
Eur J Pharmacol; 2020 Sep; 883():173305. PubMed ID: 32673673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
